A Phase III Trial Comparing Whole Brain Radiation And Stereotactic Radiosurgery Alone Versus With Temozolomide Or Erlotinib In Patients With Non-Small Cell Lung Cancer And 1-3 Brain Metastases.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Erlotinib (Primary) ; Temozolomide (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Nov 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov. (NCT00096265)
- 19 Apr 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov. (NCT00096265)
- 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00096265)